Immunic, Inc. filings document SEC reporting for a Nasdaq-listed biotechnology company developing oral therapies for neurologic disease. Recent Form 8-K reports cover financial results and corporate updates, Nasdaq minimum bid price compliance, stockholder-approved charter amendments, and the reverse stock split affecting its common stock.
Governance disclosures include director and officer appointments, executive compensation arrangements, special-meeting voting results, and definitive proxy materials. The filings also describe registered common stock, capital-structure changes, financing and clinical-program updates, and formal governance and shareholder voting subjects tied to Immunic's late-stage development model.
IMMUNIC, INC. (IMUX) reported that director Robert Thorvald Nagel received a grant of stock options covering 25,370 shares of common stock on September 16, 2026. The options have an exercise price of $10.12 per share, vest in monthly increments over one year, and expire on September 16, 2036.
The reporting person is a member of BVF Partners L.P. and is obligated to transfer any economic benefit from the sale of shares issued upon exercise of these options to BVF, and therefore disclaims beneficial ownership of the securities except to the extent of any pecuniary interest.
IMMUNIC, INC. (IMUX) reported that investment entities affiliated with Biotechnology Value Fund received a grant of 25,370 stock options on September 16, 2026, indirectly attributable to their board designee, R. Thorvald Nagel. The options have an exercise price of $10.12 per share, vest in monthly increments over one year from the grant date, and expire on September 16, 2036.
The reporting entities and Mark N. Lampert file jointly and each disclaims beneficial ownership except to the extent of pecuniary interest. A prior one-for-ten reverse stock split of IMMUNIC common stock was effective April 27, 2026, and the economic benefit from any sale of shares issuable upon exercise of these options is obligated to be transferred to BVF Partners L.P.
IMMUNIC, INC. (IMUX) reported that on September 10, 2026, Dr. Duane Nash resigned as a member of its Board of Directors. The company stated that Dr. Nash’s resignation was not due to any disagreement regarding its operations, policies, or practices. Following his resignation, the Board, by resolution, reduced its size from ten members to nine members.
IMMUNIC, INC. (IMUX) announced that it is hosting a Relapsing Multiple Sclerosis Research and Development Day webinar on September 9, 2026, from 11:00 a.m. to 12:30 p.m. Eastern Time, where management will present updates on its programs, including vidofludimus calcium.
The company is using an investor presentation for this event, furnished as Exhibit 99.1. The materials are provided under a Regulation FD disclosure framework and are expressly stated as being furnished, not filed, and therefore are not subject to certain Exchange Act liabilities nor automatically incorporated into other SEC filings.
Immunic also includes an extensive cautionary note that characterizes statements about strategy, clinical development plans, timing of trials and regulatory approvals, cash runway, Nasdaq listing, and capitalization as forward-looking statements subject to substantial risks and uncertainties, directing investors to previously filed Risk Factors for more detail.
Immunic, Inc. received a Schedule 13G reporting beneficial ownership of its common stock by OrbiMed entities. OrbiMed Advisors LLC and OrbiMed Genesis GP LLC each report beneficial ownership of 756,860 shares of common stock, representing 5.3% of the class, with shared voting and dispositive power over these shares. OrbiMed Capital LLC reports beneficial ownership of 388,540 shares, representing 2.8% of the class, with sole voting and dispositive power. The reporting persons also note holding 7.8% of the shares of common stock issuable upon exercise of warrants on behalf of other persons, over which OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power through a management committee whose members disclaim beneficial ownership.
Nantahala Capital Management, LLC and its principals Wilmot B. Harkey and Daniel Mack report beneficial ownership of Immunic, Inc. common stock on an amended Schedule 13G. As of June 30, 2026, they may be deemed to beneficially own 1,079,843 shares of common stock.
This position represents 7.47% of Immunic’s outstanding common shares. Of the reported holdings, 829,197 shares are issuable within sixty days upon exercise of convertible securities. All reported shares are held with shared voting and dispositive power through funds and separately managed accounts controlled by Nantahala; none are held with sole voting or dispositive power.
Immunic, Inc. had a Schedule 13G/A filed by Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, reporting beneficial ownership of 1,511,821 shares of Immunic common stock. As of June 30, 2026, this position represents 9.9% of the common stock, including securities issuable under warrants.
The position consists of 1,145,400 shares issuable upon exercise of a Pre-Funded Warrant and 366,421 shares underlying Tranche 1 Warrants. Both instruments are subject to a 9.99% Beneficial Ownership Limitation, and an additional 778,979 Tranche 1 Warrant shares are excluded due to that cap. Ownership percentages use 13,621,526 shares outstanding as of April 30, 2026 as the baseline.
Soleus Capital Master Fund, L.P. and related entities report beneficial ownership of 679,200 shares of Immunic, Inc. common stock, representing 4.9% of the class. The group reports shared voting and dispositive power over all 679,200 shares and no sole power.
The 679,200 shares include 114,600 shares issuable on exercise of pre-funded warrants at $0.0001 per share and 114,600 shares issuable on exercise of common warrants at $0.873220 per share. The 4.9% ownership is based on 13,644,467 shares outstanding as of July 31, 2026. Various Soleus-affiliated entities and Guy Levy disclaim beneficial ownership except for purposes of Section 13(d).
Immunic, Inc. reported second quarter 2026 results, board changes and leadership transitions while advancing its multiple sclerosis pipeline. For the quarter ended June 30, 2026, total operating expenses were $35.3 million, driven by research and development of $25.9 million and general and administrative costs of $9.4 million, both higher than the prior-year period due largely to increased personnel and non-cash stock compensation and NDA-supporting studies. Net loss was $34.1 million (basic and diluted loss of $0.80 per share).
Cash and cash equivalents were $155.1 million as of June 30, 2026, and the company expects this to fund operations into late 2027. Clinically, Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS remain on track with top-line data expected by the end of 2026, and a Phase 3 trial in progressive MS is planned to start later in 2026. Governance updates include the appointment of Elena Ridloff to the board, with an inaugural option grant for 50,740 shares, and the resignation and separation of former CEO Dr. Daniel Vitt, who moves to a consulting role and Chair of the Scientific Advisory Board under a detailed severance and consulting arrangement.
Immunic, Inc., a late-stage biotech developing oral therapies for neurologic and autoimmune diseases, reported higher operating expenses and losses for the quarter and six months ended June 30, 2026, driven mainly by Phase 3 development of vidofludimus calcium for multiple sclerosis and expanded stock-based compensation.
For the first half of 2026, operating expenses were $68.6 million versus $53.9 million a year earlier, leading to a net loss of $66.7 million. Net cash used in operating activities was $48.3 million. A February 2026 private placement raised $200 million gross ($187.3 million net), lifting cash and cash equivalents to $155.1 million and turning stockholders’ equity from a deficit to positive $127.6 million. Management states these funds are expected to support operations beyond twelve months. A 1‑for‑10 reverse stock split became effective April 27, 2026, and extensive warrants, options and SARs create a sizable pool of potential future share issuance.